Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 045396108 since 12/18/2024, largest first.
| Filer | % of Class | Filed |
|---|---|---|
| Gilead Sciences, Inc. 13D/A | 25.1% |
5/27/2026
Event 5/22/2026
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2023 Q4 | 50 | 8.68 M | $7.12 M |
| 2023 Q3 | 35 | 9.74 M | $8.62 M |
| 2023 Q2 | 34 | 10.5 M | $12.0 M |
| 2023 Q1 | 41 | 13.0 M | $10.9 M |
| 2022 Q4 | 43 | 14.3 M | $18.6 M |
| 2022 Q3 | 52 | 16.6 M | $27.2 M |
| 2022 Q2 | 57 | 17.2 M | $36.1 M |
| 2022 Q1 | 56 | 19.1 M | $39.3 M |
| 2021 Q4 | 71 | 23.3 M | $54.3 M |
| 2021 Q3 | 72 | 22.7 M | $79.0 M |
| 2021 Q2 | 101 | 27.1 M | $105 M |
| 2021 Q1 | 116 | 28.7 M | $134 M |
| 2020 Q4 | 121 | 28.2 M | $170 M |
| 2020 Q3 | 126 | 30.5 M | $502 M |
| 2020 Q2 | 111 | 30.2 M | $705 M |
| 2020 Q1 | 110 | 30.5 M | $452 M |
| 2019 Q4 | 111 | 28.7 M | $587 M |
| 2019 Q3 | 105 | 21.0 M | $206 M |
| 2019 Q2 | 117 | 21.7 M | $294 M |
| 2019 Q1 | 115 | 22.3 M | $440 M |
| 2018 Q4 | 113 | 21.6 M | $488 M |
| 2018 Q3 | 127 | 22.2 M | $823 M |
| 2018 Q2 | 114 | 16.7 M | $654 M |
| 2018 Q1 | 117 | 16.1 M | $790 M |
| 2017 Q4 | 105 | 15.6 M | $704 M |
| 2017 Q3 | 74 | 12.4 M | $432 M |
| 2017 Q2 | 68 | 12.5 M | $259 M |
| 2017 Q1 | 52 | 11.9 M | $302 M |
| 2016 Q4 | 40 | 11.7 M | $140 M |
| 2016 Q3 | 36 | 11.1 M | $79.4 M |
| 2016 Q2 | 44 | 11.3 M | $61.9 M |
| 2016 Q1 | 47 | 12.4 M | $61.6 M |
| 2015 Q4 | 50 | 12.3 M | $92.3 M |
| 2015 Q3 | 54 | 13.2 M | $126 M |
| 2015 Q2 | 58 | 12.1 M | $232 M |
| 2015 Q1 | 34 | 10.8 M | $143 M |
| 2014 Q4 | 24 | 4.30 M | $33.5 M |
| 2014 Q3 | 22 | 1.66 M | $14.1 M |